Intra-Cellular Therapies, Inc.
ITCI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $9 | $7 | $5 | $4 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $8 | $7 | $5 | $4 |
| Revenue | $1 | $0 | $0 | $0 |
| % Growth | 46.6% | 86.4% | 204.9% | – |
| Gross Profit | $1 | $0 | $0 | $0 |
| % Margin | 91.6% | 92.7% | 91.8% | 90.2% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -17.1% | -34.2% | -105.6% | -349% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -11% | -30.1% | -102.9% | -347.7% |
| EPS Diluted | -0.72 | -1.46 | -2.72 | -3.5 |
| % Growth | 50.7% | 46.3% | 22.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |